VC
KRYS icon

Vestor Capital’s Krystal Biotech KRYS Stock Holding History

Vestor Capital’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.2M Buy
700,914
+700,714
+350,357% +$209M 4.91% 2
2026
Q1 		$52K Sell
200
-2,740
-93% -$729K ﹤0.01% 256
2025
Q4 		$42K Buy
+2,940
New +$619K ﹤0.01% 260

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vestor Capital's KRYS Position: Q2 2026 in Review

Vestor Capital increased its Krystal Biotech (KRYS) stake by 350,357% in Q2 2026, buying an estimated $209M and bringing the position to 700,914 shares worth $78.2M. The position accounts for 4.91% of the portfolio, ranked #2.

Vestor Capital first reported a position in KRYS in Q4 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Vestor Capital held 700,914 shares of Krystal Biotech worth $78.2M as of Q2 2026.
  • Vestor Capital bought 700,714 Krystal Biotech shares in Q2 2026, an estimated $209M.
  • Krystal Biotech made up 4.91% of Vestor Capital's portfolio in Q2 2026, its #2 holding.
  • Vestor Capital first reported a position in Krystal Biotech in Q4 2025 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Vestor Capital's 13F filing for Q2 2026, filed 28 Jul 2026.